,1 min read
Regulatory authorities increasingly use prioritization mechanisms to manage workloads and accelerate the evaluation of applications that address public health needs or strategic objectives.
In Brazil, this approach is reflected in the priority classification system applied by ANVISA.
Priority classification is a regulatory mechanism used to assign preferential evaluation to certain petitions submitted to ANVISA. It allows specific applications—such as drug registrations, post-registration changes, or clinical trial-related submissions—to be reviewed under shortened timelines when they meet defined eligibility criteria.
The concept is formalized under RDC 1001/2025, which defines the current structure for prioritization and expands its application across different regulatory processes within the Brazilian regulatory framework.
Priority classification is not automatically granted. It depends on whether a petition aligns with criteria established by ANVISA, typically related to public health relevance, unmet medical needs, strategic national interest, or supply considerations.
While it may result in shorter review timelines, priority classification does not replace technical evaluation or guarantee approval. Instead, it determines how certain petitions are prioritized within the regulatory system.
If your organization is evaluating priority review eligibility in Brazil, connect with Freyr to assess how your product aligns with ANVISA's criteria under RDC 1001/2025.